Revelation Biosciences (REVB) Long-Term Deferred Tax (2020 - 2021)
Revelation Biosciences (REVB) posted quarterly Long-Term Deferred Tax of $821000.0 for Q4 2021, up 2245.71% year-over-year from $35000.0 in Q4 2020, and up 2245.71% quarter-over-quarter from $35000.0 in Q4 2020.
Revelation Biosciences (REVB) Long-Term Deferred Tax (2020 - 2021) Analysis & Trends
Revelation Biosciences (REVB) has reported Long-Term Deferred Tax for 2 consecutive years, with $821000.0 the latest figure, recorded in Q4 2021.
- In Q4 2021, Long-Term Deferred Tax rose 2245.71% year-over-year to $821000.0; the TTM figure through Dec 2021 stood at $821000.0 (up 2245.71% YoY), while the FY2021 annual figure was $821000.0, up 2245.71% from the prior year.
- Long-Term Deferred Tax advanced to $821000.0 in Q4 2021 per REVB's latest filing, from $35000.0 in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $821000.0 in Q4 2021 and bottomed at $35000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 821,000.00 |
| Dec 31, 2020 | 35,000.00 |